Finance

China’s biotechs bounce back after bargain-basement sale: Data Byte

Confidence roared back to investors in China biotech Wednesday, helping bellwethers Zai and BeiGene to nearly complete a roundtrip from a three-day sell-off that began on Friday following dramatic reforms that saw tutoring companies effectively...

Lumira to invest $35M ‘bespoke’ fund with Italy’s Angelini as sole backer

Two days after Lumira announced the closing of its $220 million fourth fund, the firm has identified Angelini as the sole investor in the $35 million Angelini Lumira Biosciences Fund, a separate vehicle designed to...

Rout extends, but long view shows biotech passing tech: a BioCentury Data Byte

As bad as the past three days have been for investors in China’s biopharmas, a long-term view demonstrates the strength of the sector compared with tech and the broader market. The China BioPharma ETF...

China’s market jitters clip biopharma shares

Concerns that biopharma could become the next industry to be scrutinized by Beijing sent shares falling in Hong Kong and New York Monday after a government directive related to the education sector has...

Seeking deals from all areas of U.S. and Canada, Lumira raises $220M fourth fund

Canada’s Lumira Ventures expects to invest its largest fund yet across North America, with particular emphasis on geographies less well served by other biotech VCs. The firm believes it’s the largest institutional life sciences venture capital...

Caribou gives back early gains after pricing $304M IPO

Continued enthusiasm for gene editing stocks helped drive demand for Caribou’s upsized, $304 million IPO, as the company’s shares rose by as much as 23% early in their first day of trading before...

July 22 Quick Takes: Anocca’s $47M B round to support Swedish biotech’s T cell pipeline

In Sweden’s largest biotech venture round of the year, Anocca AB raised $47 million in a series B round to advance the company’s cellular biology technology and pipeline of TCR-modified T cell therapies. Danske Bank...

Corporate venture investments by modality: Data Byte

While companies working on established modalities including small molecules, mAbs and proteins comprised more than half of venture rounds backed by corporate VCs last year, this subset of investors is also beginning to dip its...

French gene therapy play Coave rebrands with €21.2M series B extension

With €21.2 million ($25.1 million) in additional series B funding backed by a European syndicate, Paris-based Coave plans to advance its pipeline of targeted gene therapies for CNS and rare ocular diseases.  Seroba Life Sciences led...

Qiming looks to tap China’s public biotech boom

Qiming is joining other high-profile investors in China’s burgeoning healthcare sector by launching its first vehicle to invest in public equities with more than $500 million, sources familiar with the matter told BioCentury. Springhill Fund...

Italy’s Panakès now targeting therapeutics with second fund

Panakès’ experience investing its first fund in medtech companies has led the Italian firm to branch into therapeutics for its Purple Fund, a new vehicle that has completed a first close at €150 million....

To Hong Kong via the Caymans, Maryland siRNA play Sirnaomics looks to list at last

On the heels of two $105 million venture financings, siRNA company Sirnaomics revealed in a filing to the Hong Kong stock exchange that it has incorporated itself in the Cayman Islands as it seeks to...

China-based biopharmas have raised collective $4.1B in IPOs this year: Data Byte

Sixteen Chinese biopharmas have raised a combined total of over $4.1 billion across IPOs on NASDAQ, the Hong Kong stock exchange and Shanghai’s STAR board in 2021, according to BioCentury’s BCIQ database, putting the industry...

Shape raises $112M B round to grow RNA platform

Amid growing investor interest in RNA modalities, Shape raised a $112 million series B round co-led by Decheng Capital and Breton Capital to advance a suite of programs that target, edit and replace RNA.  While...

Wugen secures $172M series B to advance memory NK, CAR T cell therapies

After adding memory NK cells to its cell therapy tool kit last year, Wugen has raised $172 million in a series B round led by Abingworth and Tybourne Capital to advance multiple off-the-shelf therapies for...